Doherty Elizabeth L, Aw Wen Yih, Hickey Anthony J, Polacheck William J
Joint Department of Biomedical Engineering, University of Carolina at Chapel Hill and North Carolina State University, Chapel Hill, NC, United States.
University of North Carolina Catalyst for Rare Diseases, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.
Front Bioeng Biotechnol. 2021 Feb 4;9:624435. doi: 10.3389/fbioe.2021.624435. eCollection 2021.
Over the past decade, advances in microfabrication and biomaterials have facilitated the development of microfluidic tissue and organ models to address challenges with conventional animal and cell culture systems. These systems have largely been developed for human disease modeling and preclinical drug development and have been increasingly used to understand cellular and molecular mechanisms, particularly in the cardiovascular system where the characteristic mechanics and architecture are difficult to recapitulate in traditional systems. Here, we review recent microfluidic approaches to model the cardiovascular system and novel insights provided by these systems. Key features of microfluidic approaches include the ability to pattern cells and extracellular matrix (ECM) at cellular length scales and the ability to use patient-derived cells. We focus the review on approaches that have leveraged these features to explore the relationship between genetic mutations and the microenvironment in cardiovascular disease progression. Additionally, we discuss limitations and benefits of the various approaches, and conclude by considering the role further advances in microfabrication technology and biochemistry techniques play in establishing microfluidic cardiovascular disease models as central tools for understanding biological mechanisms and for developing interventional strategies.
在过去十年中,微制造和生物材料的进展推动了微流控组织和器官模型的发展,以应对传统动物和细胞培养系统所面临的挑战。这些系统主要是为人类疾病建模和临床前药物开发而开发的,并越来越多地用于理解细胞和分子机制,特别是在心血管系统中,其独特的力学和结构在传统系统中难以重现。在这里,我们回顾了最近用于模拟心血管系统的微流控方法以及这些系统提供的新见解。微流控方法的关键特性包括在细胞长度尺度上对细胞和细胞外基质(ECM)进行图案化的能力以及使用患者来源细胞的能力。我们将综述重点放在利用这些特性来探索心血管疾病进展中基因突变与微环境之间关系的方法上。此外,我们讨论了各种方法的局限性和优点,并通过考虑微制造技术和生物化学技术的进一步进展在建立微流控心血管疾病模型作为理解生物学机制和开发干预策略的核心工具方面所起的作用来得出结论。